About this Research Topic
Alzheimer's Disease (AD) and related dementias affect over 55 million individuals globally, posing a significant challenge due to the lack of effective therapies that can halt or reverse disease progression. The complexity of AD's cellular and molecular aetiology has hindered the development of curative treatments. The first drugs approved for AD treatment in the early 2000s only manage to slow disease progression without altering its underlying pathology. However, recent advancements in disease-modifying drugs, particularly monoclonal antibodies targeting amyloid β (Aβ), have shown promise in developing effective therapies. These advancements highlight the potential of advanced therapy medicinal products, such as gene, RNA, and cell therapies, which aim to target altered molecular mechanisms in a tailored manner. Despite these promising developments, there remains a need for further research to fully understand and harness these innovative therapeutic strategies.
This Research Topic aims to encourage scientists to focus on the most promising and innovative studies for gene and cell therapy for AD and related disorders. The primary objective is to explore new insights into AD pathophysiology, identify novel therapeutic targets, and develop advanced therapeutic strategies that can modify the disease course. Researchers are invited to address specific questions related to the efficacy and safety of these therapies, as well as to test hypotheses regarding their potential to provide breakthrough treatments for AD.
To gather further insights into the advanced therapeutic approaches for Alzheimer's Disease, we welcome Original Research and Review articles addressing, but not limited to, the following themes:
• New insights into AD pathophysiology with a focus on targets for disease-modifying drug development
• Novel gene-, RNA-, or cell-based therapies for AD
• Off-label or repurposed treatment strategies for AD with existing biopharmaceuticals as well as gene and cell therapy
• Delivery strategies for novel advanced therapy medicinal products in AD
• Clinical trials involving gene, RNA, and/or cell therapies in patients
• Obstacles to equitable access for advanced AD therapies
This Research Topic aims to encourage scientists to focus on the most promising and innovative studies for gene and cell therapy for AD and related disorders. The primary objective is to explore new insights into AD pathophysiology, identify novel therapeutic targets, and develop advanced therapeutic strategies that can modify the disease course. Researchers are invited to address specific questions related to the efficacy and safety of these therapies, as well as to test hypotheses regarding their potential to provide breakthrough treatments for AD.
To gather further insights into the advanced therapeutic approaches for Alzheimer's Disease, we welcome Original Research and Review articles addressing, but not limited to, the following themes:
• New insights into AD pathophysiology with a focus on targets for disease-modifying drug development
• Novel gene-, RNA-, or cell-based therapies for AD
• Off-label or repurposed treatment strategies for AD with existing biopharmaceuticals as well as gene and cell therapy
• Delivery strategies for novel advanced therapy medicinal products in AD
• Clinical trials involving gene, RNA, and/or cell therapies in patients
• Obstacles to equitable access for advanced AD therapies
Keywords: RNA, Bench-to-bedside research, DMTs (disease-modifying therapy), Gene Therapy, Cell Therapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
